累积靶区剂量对远端食管癌IMPT肿瘤反应的影响
本研究回顾性分析2020至2024年135例接受新辅助放化疗联合调强质子治疗(IMPT)的远端食管癌患者,每周重复CT评估累积ITV剂量。结果显示21%患者出现ITV剂量不足,但GTV覆盖均保持,且ITV剂量不足与肿瘤反应或总生存无关联。
要点
- 21%远端食管癌IMPT患者出现ITV剂量不足,但无GTV剂量不足。
- ITV剂量不足与12个月持续cCR或pCR无显著关联。
- 基线膈肌振幅>2 cm与靶区剂量不足无关,2年OS两组均为64%。
核心结论
- 尽管ITV剂量不足常见,GTV覆盖仍保持,且未观察到与肿瘤反应或OS的关联。
- 基线膈肌振幅单独不构成排除IMPT治疗的理由。
研究设计与样本
- 回顾性评估2020至2024年135例接受新辅助放化疗联合IMPT的远端食管癌患者。
- 每周重复CT评估累积ITV剂量,采用稳健体素最小剂量标准(ITV D98%<94%)。
- 主要终点为12个月持续临床完全缓解(cCR)和病理完全缓解(pCR)。
主要发现
- 中位基线膈肌振幅1.6 cm(范围0.5-8.7 cm)。
- ITV剂量不足发生于21%患者,未观察到GTV剂量不足病例。
- ITV剂量不足与无剂量不足患者治疗后cCR率无差异(p=0.90)。
- 持续cCR或pCR在ITV剂量不足组为28%,无剂量不足组为30%。
- 基线膈肌振幅>2 cm与靶区剂量不足无关,两组2年OS均为64%(p=0.7)。
关键数值与推荐
- ITV剂量不足定义为稳健体素最小剂量标准下ITV D98%<94%。
- 完全肿瘤反应定义为12个月持续cCR或pCR。
临床怎么用
- 远端食管癌IMPT治疗中即使ITV剂量不足,GTV覆盖仍可保持,不必仅因基线膈肌振幅>2 cm排除IMPT。
- 需关注累积ITV剂量,但ITV剂量不足未必影响肿瘤反应或生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In esophageal cancer, respiratory motion and anatomical changes can compromise dose delivery during proton radiotherapy. Adequate internal target volume (ITV) coverage does not necessarily ensure sufficient gross tumor volume (GTV) dose, particularly for distal tumors near the diaphragm. This study evaluated whether deviations in accumulated target dose affect tumor response. METHODS: We retrospectively evaluated 135 patients with distal esophageal cancer treated with neoadjuvant chemoradiotherapy and intensity-modulated proton therapy (IMPT) between 2020 and 2024. Accumulated ITV dose was assessed weekly on repeat CTs using a robust voxel-wise minimum dose criterion (ITV D98 % < 94 %). Cumulative dose deposition was estimated using robust dose accumulation. Primary endpoints were persistent clinical complete response (cCR) at 12 months and pathologic complete response (pCR). Secondary endpoints included post-treatment cCR and two-year overall survival (OS). RESULTS: Median baseline diaphragm amplitude was 1.6 cm (range 0.5-8.7 cm). ITV underdosage occurred in 21 % of patients. No cases of GTV underdosage were observed. Post-treatment cCR rates did not differ between patients with and without ITV underdosage (p = 0.90). Complete tumor response, defined as persistent cCR at 12 months or pCR, was observed in 28 % and 30 % of patients with and without ITV underdosage, respectively. Baseline diaphragm amplitude > 2 cm was not associated with target underdosage, and two-year OS was similar between groups (64 % vs. 64 %, p = 0.7). CONCLUSIONS: Despite frequent ITV underdosage, GTV coverage remained preserved and no association with tumor response or OS was observed. Baseline diaphragm amplitude alone does not appear to warrant exclusion from treatment with IMPT.
引用
- van Keeken K, Badiu V, Vilches-Freixas G, et al. Impact of accumulated target dose on tumor response in distal esophageal cancer treated with intensity-modulated proton therapy. Radiother Oncol. 2026. PMID: 42763050. doi:10.1016/j.radonc.2026.111788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。